EIF4A3 and neoplasm: In particular, EIF4A3‐silencing in vivo in established subcutaneous tumours significantly reduced tumour growth (p‐value < .0001) (Figure 3H) and final tumour weight (Figure 3I) compared to scramble‐treated tumours (p‐value < .04).